FDA Advisory Panel Unanimously Recommends Moderna's Flu Vaccine for Adults 50 and Older
Presented by Planned Parenthood {beacon} Healthcare Health Care PRESENTED BY The Big Story FDA panel gives nod to Moderna flu shot The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. The shot is...
An independent advisory panel for the U.S. Food and Drug Administration (FDA) has unanimously voted 9-0 in favor of Moderna's mFlusiva influenza vaccine. The panel determined that the benefits of the vaccine outweigh the risks for individuals aged 50 and older. This recommendation covers both the 50-64 age group and those 65 and above. The unanimous decision signifies strong confidence in the vaccine's safety and efficacy profile. This marks a significant step towards potential approval and wider availability of the new flu shot. The FDA will now consider the panel's recommendation in its final decision-making process. This development could offer a new option for flu prevention in older adults. Public health officials will likely monitor its uptake and impact.
An FDA panel's unanimous recommendation for Moderna's flu vaccine for adults 50+ suggests a potentially significant new tool for influenza prevention in this age group.
📌 Kaynak
Bu haber XML kaynağından derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →